Skip to main content
COGNITION THERAPEUTICS INC logo

COGNITION THERAPEUTICS INC — Investor Relations & Filings

Ticker · CGTX ISIN · US19243B1026 US Professional, scientific and technical activities
Open in API
Filings indexed 281 across all filing types
Latest filing 2023-03-28 Regulatory Filings
Country US United States of America
Listing US CGTX

About COGNITION THERAPEUTICS INC

https://cogrx.com/

Cognition Therapeutics, Inc. is a clinical-stage neuroscience company that discovers and develops oral, small-molecule therapeutics for neurodegenerative disorders. The company's primary focus is on conditions such as Alzheimer's disease and Dementia with Lewy Bodies (DLB). Its therapeutic approach is centered on developing medications designed to target and modulate key cellular damage response mechanisms. By aiming to rescue trafficking deficits and restore normal cellular housekeeping functions, the company seeks to protect neurons, improve synaptic health, and ultimately address the cognitive decline associated with these diseases.

Recent filings

Filing Released Lang Actions
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text indicates it is a 'Current Report' pursuant to the Securities Exchange Act of 1934, dated March 28, 2023. The content describes the company issuing a press release about clinical study results and includes the press release as an exhibit. There are no financial statements or detailed financial data presented, only an announcement of an event and a press release. The document length is 3501 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories and includes current reports like Form 8-K that announce events without detailed financial data.
2023-03-28 English
424B5
Capital/Financing Update Classification · 95% confidence The document is a prospectus supplement filed pursuant to Rule 424(b)(5) related to a registration statement on Form S-3. It discusses the offering and sale of common stock under a Controlled Equity Offering Sales Agreement. The document includes details about the offering limits, sales agents, and legal matters related to the offering. It is not a full financial report, earnings release, or management discussion, but rather a capital raising document supplementing a prior prospectus. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is 4413 characters, which is consistent with a detailed supplement rather than a brief announcement or a full report.
2023-03-27 English
FORM S-8
Regulatory Filings Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC by Cognition Therapeutics, Inc. It registers additional shares under the company's 2021 Equity Incentive Plan. The document includes legal and procedural information about the registration of shares for employee benefit plans, references to prior filings, and signatures of company officers. It is not a financial report, earnings release, or management discussion, but a regulatory filing related to securities registration. Form S-8 is a specific SEC registration form for securities to be offered under employee benefit plans, which falls under the category of Regulatory Filings (RNS) in the given classification scheme.
2023-03-23 English
10-K
Annual Report FY 2022
2023-03-23 English
FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated March 23, 2023, reporting the results of operations and financial condition for the year ended December 31, 2022. It references a press release announcing financial results and explicitly states that the press release is furnished as an exhibit. The document itself is short (3901 characters) and primarily serves as a current report to announce the earnings release rather than containing detailed financial statements or analysis. According to the rules, such a document that announces financial results but does not contain the full financial data or detailed analysis is classified as an Earnings Release (ER).
2023-03-23 English
FORM 8-K
Regulatory Filings Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text includes a press release about FDA clearance for a drug candidate and plans for a Phase 2 trial. There are no financial statements or detailed financial data included. The document length is 3625 characters, which is relatively short and mainly contains an announcement of an event rather than a full report. According to the rules, such filings that announce events or press releases without substantive financial data or detailed reports should be classified as Regulatory Filings (RNS).
2023-03-15 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.